InMed amends Armistice option exercise price from $16.60 to $0.80 per share

InMed Pharmaceuticals Inc.

Up to 278,761 common shares subject to options; exercise price reduced to $0.80 from $16.60.
Options originally issued October 26, 2023; amendment entered May 18, 2026.
Dramatic price reduction may increase dilution risk for existing shareholders if exercised.
Press release issued May 19, 2026 confirms amendment; no assurance options will be exercised.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

InMed Pharmaceuticals Inc. amended Armistice Preferred Investment Option Amending Agreement with Armistice Capital Master Fund Ltd. (effective 2026-05-18).

Action: amendment
Agreement: equity purchase
Counterparty: Armistice Capital Master Fund Ltd.
Effective: 2026-05-18

Exact text from the filing

On May 18, 2026, the Company entered into a preferred investment option amending agreement (the "Armistice Preferred Investment Option Amending Agreement") with Armistice to amend the Armistice Exercise Price contained in the Armistice Preferred Investment Options from $16.60 to $0.80.

View on SEC.gov

197 material agreements filed in the last 30 days. Browse all material agreements →

InMed Pharmaceuticals Inc. filing history →

Source: SEC EDGAR

accession 0001062993-26-002787

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.